Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
bioAffinity Technologies, Inc. ( (BIAF) ) has provided an announcement.
On October 20, 2025, bioAffinity Technologies announced its participation in CHEST 2025, where they will present research supporting the CyPath® Lung test’s methods for collecting and transporting patient samples. The study highlights the test’s ability to detect early-stage lung cancer with high sensitivity and specificity, potentially improving patient outcomes.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Underperform.
The overall stock score is primarily driven by the company’s weak financial performance and bearish technical indicators. The negative P/E ratio and lack of dividend yield further contribute to the low score. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics for lung cancer and other lung diseases. Their primary product, CyPath® Lung, is a noninvasive test marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Average Trading Volume: 2,781,269
Technical Sentiment Signal: Sell
Current Market Cap: $13.23M
Learn more about BIAF stock on TipRanks’ Stock Analysis page.